|
|
 | | | |
- close
- close
- close
- close
Nektar Therapeutics (NKTR) |
QUOTE AND NEWS
PR Newswire
Apr 10
Comment
SAN FRANCISCO, April 10, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16, 2012 from 12:00 p.m. to 5:00 p.m. ET in New York
Benzinga
Apr 2
Comment
Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate....
Benzinga
Mar 28
Comment
Nektar Therapeutics (NASDAQ: NKTR) today reported that its partner Affymax, Inc. (NASDAQ: AFFY) announced that the U.S. Food and Drug Administration has approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney...
FierceBiotech
Mar 20
Comment
Nektar Therapeutics ($NKTR) has announced a move to consolidate all of its U.S. research and development at its Mission Bay location in San Francisco. The company, a maker and developer of PEGylated drugs, plans to relocate 30 R&D workers from its...
Benzinga
Feb 29
Comment
Shares of Nektar Therapeutics (NASDAQ: NKTR) are up 7% after the company agreed to sell some of its royalty agreements to Royalty Pharma for $124 million.
The company today announced that it agreed to sell to Royalty Pharma its royalties on...
StreetInsider.com
Feb 27
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Nektar+%28NKTR%29+Reports+%27Statistically+Meaningful%27+Data+for+NKTR-181/7215128.html for the full story.
Benzinga
Jan 20
Comment
Bank of America lowers its rating on Nektar Therapeutics (NASDAQ: NKTR) to Underperform from Neutral and maintains its $6 price target as risks offset the company's potential upside in 2012.
Bank of America says, "We see two key risks in 2012...
Marketwire
Jan 13
Comment
HONG KONG -- (Marketwire) -- 01/13/12 -- Today, www.BollingerReport.com introduced featured coverage of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Nektar Therapeutics (NASDAQ: NKTR). Full research reports are available to readers at:
StreetInsider.com
Dec 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Nektar+%28NKTR%29+Initiates+NKTR-102+Phase+3+in+Women+with+Metastatic+Breast+Cancer/7011010.html for the full story.
Benzinga
Nov 15
Comment
Nektar Therapeutics (NASDAQ: NKTR)
today presented positive preclinical data for NKTR-102, a next-generation
topoisomerase I inhibitor, at the 2011 AACR-NCI-EORTC International Conference
on Molecular Targets and Cancer being held in San...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
